에 대한 최신 뉴스 Danaher (NYSE:DHR) 주식

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Social Media

Exclusives

Tech

Trading Ideas

LAES

MRVL

SNAP

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 스냅, 실스크, 버티브, 다나허 및 마벨 테크놀로지

Analyst Color

Earnings

Equities

News

Guidance

Health Care

Price Target

Reiteration

Analyst Ratings

General

화요일에, 다나허(NYSE:DHR)는 3분기 매출이 57억 9천만 달러로 전년 대비 3% 증가했으며, 컨센서스 55억 9천만 달러를 상회했다고 보고했다. 가이던스: 다나허(Danaher)는 2024 회계연도 비GAAP 핵심 매출이 전년 대비 낮은 한 자릿수로 감소할 것임을 재확인했다.

다나허의 3분기 실적은 바이오프로세싱 주문 증가로 인해 증가, 분석가는 주식 등급 유지

Movers

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

SPOT

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? QXO(NASDAQ:QXO)의 주가는 사모 금융 유치를 발표한 이후 33.37% 상승했다.

유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 4.42% on an annualized basis producing an average annual return of 15.75%. Currently, Danaher has a market capitalization of $173.73 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $431.90 today based on a price of $240.53 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736953210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT.
<ul>
<li>For the fourth quarter 2024, estimated revenues are anticipated to increase in the low-single digit percent range year-over-year.</li>
<li>Estimated non-GAAP core revenue for the fourth quarter of 2024 is expected to be essentially flat year-over-year, which would be above the Company's previously announced guidance of a low-single digit percent decline.</li>
</ul>

Danaher CEO Says "For Q4 2024, Estimated Revenues Are Anticipated To Increase In The Low-Single Digit Percent Range YoY; Estimated Non-GAAP Core Revenue For Q4 2024 Is Expected To Be Essentially Flat YoY, Which Would Be Above The Company's Previously Announced Guidance Of A Low-Single Digit Percent Decline"

<ul>
<li>Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions.</li>
<li>Investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.</li>
</ul>

Reported Earlier, Danaher Forms Investment Partnership With Innovaccer To Advance AI-Driven Precision Diagnostics

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $305 to $285.

Citigroup Maintains Buy on Danaher, Lowers Price Target to $285

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 3.73% on an annualized basis producing an average annual return of 15.04%. Currently, Danaher has a market capitalization of $167.03 billion. 
Buying $1000 In DHR: If an investor had bought $1000 of DHR stock 10 years ago, it would be worth $4,085.24 today based on a price of $231.26 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735831809_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 3.64% on an annualized basis producing an average annual return of 14.74%. Currently, Danaher has a market capitalization of $164.51 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $392.62 today based on a price of $227.76 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735048812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years

Analysts' ratings for Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) over the last quarter vary from bullish to bearish, as provided by 14 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $293.29, a high estimate of $315.00, and a low estimate of $265.00. Highlighting a 0.58% decrease, the current average has fallen from the previous average price target of $295.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1734976812_0_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Danaher by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$265.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Doug Schenkel</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$285.00</td>
<td>-</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$311.00</td>
<td>$333.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Paul Knight</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$265.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$305.00</td>
<td>$309.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$275.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$278.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$315.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Danaher. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Danaher compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Danaher's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Danaher's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Danaher analyst ratings.</a>
<h2>Delving into Danaher's Background</h2>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Breaking Down Danaher's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Danaher's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 3.09%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Danaher's net margin excels beyond industry benchmarks, reaching 14.11%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Danaher's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.62% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Danaher's ROA excels beyond industry benchmarks, reaching 1.03%. This signifies efficient management of assets and strong financial health.
Debt Management: Danaher's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.34.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

14 Analysts Have This To Say About Danaher

Scotiabank analyst Sung Ji Nam initiates coverage on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Sector Perform rating and announces Price Target of $265.

Initiation

Scotiabank Initiates Coverage On Danaher with Sector Perform Rating, Announces Price Target of $265

Few hedge fund managers command the attention of Wall Street quite like Dan S. Loeb. As the founder of Third Point, a $7 billion hedge fund, Loeb has made his mark with bold activist strategies that challenge the status quo and drive <a href="https://www.benzinga.com/general/hedge-funds">transformation in global companies.</a>
<h3 class="wp-block-heading">Portfolio Overview</h3>
As of Q3 2024, Third Point's portfolio is valued at $7.37 billion, comprising 41 investments. The fund gained 5.3% during the quarter, with top holdings including Pacific Gas &amp; Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) at 13%, Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) at 9.3%, and Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) at 7.3%. Smaller positions include Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) and Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>), each at 5.1%.
Best Performers: These five stocks have surged over 20% in the last 6 months.
<ol>
<li>Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) escalated around 43%.</li>
<li>Amazon surged about 18%</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) rose roughly 17%</li>
<li>Corpay, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) rocketed about 29%</li>
<li>Cinemark Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) increased approximately 60%</li>
</ol>
These gains highlight Loeb's ability to capitalize on growth opportunities across the entertainment, tech, and financial sectors.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42615908/feds-preferred-inflation-gauge-falls-more-than-expected-markets-breathe-sigh-of-relief">Fed&#8217;s Preferred Inflation Gauge Falls More Than Expected: Markets Breathe Sigh Of Relief</a>
Investment Strategy:
<ul>
<li>Loeb is a prominent activist investor who acquires significant stakes in underperforming companies to advocate for improvements in management, operations, or governance, with the goal of enhancing shareholder value. A key example is his 2011 investment in Yahoo, where a 5% stake and strategic push led to transformations and over $1 billion in gains, <a href="https://hedgefundalpha.com/dan-loeb-portfolio/">according </a>to Hedge Fund Alpha.</li>
<li>Throughout his career, Loeb has focused more on creating spin-offs than investing in existing ones. He recently applied his activist strategy with Sony and Shell to pursue spin-offs, <a href="https://www.cnbc.com/2021/10/28/shell-vs-activist-dan-loeb-is-bigger-for-big-oil-than-exxon-board-war.html">according </a>to CNBC, but was unsuccessful in these efforts.</li>
<li>Beyond equities, Loeb explores opportunities in credit markets, including distressed debt and corporate bonds, aiming to generate high-risk-adjusted returns by exploiting inefficiencies in those areas. In 2012, Loeb invested in Greek sovereign bonds during the financial crisis, assessing the risk-reward ratio and achieving strong returns, adding to an already successful year, CNBC <a href="https://www.cnbc.com/2012/10/03/third-points-loeb-bets-big-and-wins-on-greek-debt.html">reported</a>.</li>
</ul>
Historical Performance: Since launching in 1995, the fund has averaged annual returns of 16%, attracting new investors with consistent positive performance, according to Hedge Fund Alpha.
Loeb's major successes came during the dot-com bubble and the 2008 financial crisis, with his fund posting a 45% return in 2009 despite a market downturn.
Third Point&#8217;s assets under management reportedly peaked at nearly $18 billion in 2022 before declining to approximately $7 billion, attributed to underperformance during a challenging market period in 2022. By the end of 2023, the fund achieved modest positive returns, indicating some stabilization.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41397978/hedge-fund-billionaire-daniel-loeb-bets-on-trump-win-singles-out-this-recent-buy-as" target="_blank" rel="noreferrer noopener">Hedge Fund Billionaire Daniel Loeb Bets On Trump Win, Singles Out This Recent Buy As Having &#8216;Significant Upside Potential&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Hedge Funds

AMZN

BBWI

CPAY

5 High-Flying Stocks In Dan Loeb's Portfolio: Cinemark, Corpay, Amazon Lead

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week ending Dec. 13:
Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>): The social media and messaging company saw strong interest from Benzinga readers during the week, which is likely related to the <a href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling">continued fight to ban</a> TikTok in the U.S. 
Snap and TikTok social media rivals such as Facebook, Instagram and Reddit could benefit if the app is banned. TikTok lost a fight with the U.S. appeals court recently with parent company ByteDance facing a deadline of Jan. 19, 2025, to sell the U.S. arm to a non-Chinese owner or face app stores removing the platform in America. 
While this could be good news for Snap, the ban is far from over with ByteDance continuing to fight and also concerns that President-elect Donald Trump could halt the ban when he takes over the White House. Snap and other social media platforms are also being targeted <a href="https://www.benzinga.com/24/11/42237670/meta-tiktok-snapchat-could-face-32m-fines-as-australia-enforces-social-media-ban-for-under-16s-while-exempting-youtube">in several countries </a>and states over age restrictions on usage of the platforms, which could push the stock down further.
Snap stock was down on the week, as shown on the Benzinga Pro chart below. The stock is down 30% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268.png" alt="" class="wp-image-692032" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268-768x385.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>): The microchip company saw shares surge on several news items related to drones. The company <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42447155/sealsq-corp-shares-are-up-by-more-than-90-what-you-need-to-know">announced partnerships </a>with leading drone manufacturers Parrot and AgEagle. 
The company plans to launch its new Quantum-Resistant Secure Chips portfolio in 2025, which could keep the stock on the radar of Benzinga readers. Testing for these chips is underway. SEALSQ also<a href="https://www.benzinga.com/24/12/42466578/whats-going-on-with-sealsq-corp-today"> announced a partnership</a> with IC'ALPS to accelerate the development of secure Application Specific Integrated Circuits.
"By combining agility with innovation, we are setting a benchmark for excellence in the competitive global semiconductor industry," SEALSQ CTO Jean Pierre Enguent said.
The drone market has been hot with investors looking for the company's that could benefit from the increase in commercial and military drone applications. Shares of the company surged over 200% on the week.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269.png" alt="" class="wp-image-692033" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>): The critical power and infrastructure company saw strong interest from readers during the week. 
Bank of America analyst Andrew Obin <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42072226/vertivs-earnings-estimates-raised-by-analyst-amid-improved-margin-outlook">recently reiterated a Buy</a> rating with a price target of $150 on the stock. The analyst said the company revised its organic revenue growth forecast to 12%-14% CAGR for 2024 to 2029, up from prior guidance of 8%-11%. Other analysts have<a href="https://www.benzinga.com/quote/VRT/analyst-ratings"> added their takes</a> on the company recently with Barclays initiating shares with an Equal-Weight rating and $142 price target and Citigroup maintaining a Buy rating and raising the price target from $141 to $155.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270.png" alt="" class="wp-image-692034" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270-768x391.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>): The scientific instrument manufacturing company saw increased interest from readers during the week. 
The stock, which previously was featured on the Stock Whisper Index<a href="https://www.benzinga.com/top-stories/24/06/39551432/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet"> in June</a>, saw an analyst upgrade send shares higher on the week. Bank of America upgraded shares from Neutral to Buy with a price target of $290. The analyst said strategic partnerships and pricing could help drive future growth. 
Danaher reported third-quarter financial results in October with earnings per share and revenue each beating Street forecasts. The company has beaten analyst estimates in more than 10 straight quarters for both revenue and earnings per share. Fourth-quarter earnings are estimated to be in January, which could be a future catalyst for the stock.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271.png" alt="" class="wp-image-692035" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Marvell Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>): The semiconductor stock is trading higher on the week, which comes with peers reporting results and less than two weeks after the company<a href="https://www.benzinga.com/news/earnings/24/12/42302752/marvell-technology-stock-climbs-after-better-than-expected-q3-results-strong-q4-guidance"> reported third-quarter</a> financial results on Dec. 3. The company beat analyst estimates for both revenue and earnings per share. 
Marvell CEO Matt Murphy highlighted the company's forecast for the fourth quarter, which is driven by custom AI silicon programs that are in volume production. The company recently <a href="https://www.benzinga.com/news/contracts/24/12/42432652/marvell-debuts-game-changing-lpo-chipset-for-data-centers-details">announced the availability </a>for new chips in its interconnect portfolio, which comes as AI-driven data centers could boost the need for optimizing interconnect solutions. 
Several analysts <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/12/42321281/marvell-technology-posts-solid-q3-beat-analysts-raise-forecasts-expect-40-50-earnings-growth">raised their price targets</a> on the stock after the company's third-quarter financial results. Shares are up over 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272.png" alt="" class="wp-image-692036" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42013739/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-43" target="_blank" rel="noreferrer noopener">November 15</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/42144099/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-44" target="_blank" rel="noreferrer noopener">November 22</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/11/42250431/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-45" target="_blank" rel="noreferrer noopener">November 29</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42366750/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">December 6</a></li>
</ul>
Read Next: 
<ul>
<li><a href="http://=https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42353047/exclusive-volt-etf-taps-7-trillion-electrification-boom-fueled-by-ai-power-demand">EXCLUSIVE: VOLT ETF Taps $7 Trillion Electrification Boom Fueled By AI Power Demand</a></li>
</ul>

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed.
For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections.
Looking ahead to fiscal year 2025, initial forecasts and management comments suggest a mixed outlook.
The first half of the year is expected to mirror the challenges of late fiscal year 2024, while the second half could see improvement due to easier year-over-year comparisons, potential economic stimulus in China, and a broader market recovery.
After being cautious for most of the past year, the analyst sees some positive signs. The bioprocess market, important for certain Core Tools vendors, has been improving steadily and is expected to stabilize in 2025.
Although China&#8217;s stimulus has taken longer than expected, it is starting to lead to some new orders.
Valuations are still higher than the historical average, but they aren&#8217;t as high as in previous years, creating some good opportunities for stock picking.
BofA upgraded Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) to Buy from Neutral, maintaining the <a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener">price target of $290</a>.
In 2024, Danaher struggled with challenges like reduced bioprocessing inventory, a slowdown in China, and lower spending from biotech and pharma customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41465140/danahers-q3-earnings-boosted-by-bioprocessing-order-growth-analyst-maintain-stock-r" rel="noreferrer noopener">Danaher&#8217;s Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating</a>
Analysts believe that bioprocessing, an important market, is nearly back to normal and should see steady demand in 2025.
Although China is still facing difficulties, BofA expects a strong increase in orders in the fourth quarter due to stimulus efforts, with positive effects likely starting in 2025.
BofA has also upgraded Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) from Neutral to Buy with a <a target="_blank" href="https://www.benzinga.com/quote/RVTY/analyst-ratings" rel="noreferrer noopener">price target of $138</a>.
The company is at a turning point after making significant business changes in recent years. While management did not provide guidance for fiscal year 2025 at the recent Analyst Day, the long-term strategy remains largely the same.
Even though the market is stabilizing in FY25, Revvity&#8217;s growth is expected to be below its 6-8% target range. As short-term industry challenges continue to lessen, BofA expects Revvity to perform well, bolstered by recent acquisitions.
Price Action: At last check Friday, DHR stock was down 0.15% at $234.14, and RVTY stock was down 1.56% at $114.21.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42488323/drug-price-hikes-unsupported-by-evidence-cost-us-815-million-icer-report" target="_blank" rel="noreferrer noopener">Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report</a></li>
</ul>

Large Cap

Upgrades

RVTY

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

B of A Securities analyst Derik De Bruin upgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Neutral to Buy and maintains the price target from $290 to $290.

B of A Securities Upgrades Danaher to Buy, Maintains Price Target to $290

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$270.00</td>
<td>$126.0K</td>
<td>711</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$160.00</td>
<td>$162.3K</td>
<td>2.0K</td>
<td>939</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$310.00</td>
<td>$54.2K</td>
<td>71</td>
<td>742</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$830.00</td>
<td>$28.3K</td>
<td>2.0K</td>
<td>520</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$600.00</td>
<td>$96.7K</td>
<td>17</td>
<td>474</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$240.00</td>
<td>$279.3K</td>
<td>1.0K</td>
<td>306</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$25.00</td>
<td>$89.1K</td>
<td>8.4K</td>
<td>289</td>
</tr>
<tr>
<td>MEDP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$25.8K</td>
<td>224</td>
<td>178</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$25.00</td>
<td>$29.4K</td>
<td>4.1K</td>
<td>145</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$390.00</td>
<td>$28.2K</td>
<td>348</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on December 13, 2024. This event was a transfer of 618 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $126.0K, with a price of $205.0 per contract. There were 711 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 106 day(s) on March 21, 2025. This event was a transfer of 800 contract(s) at a $160.00 strike. The total cost received by the writing party (or parties) was $162.3K, with a price of $203.0 per contract. There were 2021 open contracts at this strike prior to today, and today 939 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option sweep with bullish sentiment. It expires in 197 day(s) on June 20, 2025. Parties traded 21 contract(s) at a $310.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $2582.0 per contract. There were 71 open contracts at this strike prior to today, and today 742 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be neutral, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 13 contract(s) at a $830.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $2176.0 per contract. There were 2007 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on December 27, 2024. Parties traded 117 contract(s) at a $600.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $96.7K, with a price of $830.0 per contract. There were 17 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on December 6, 2024. Parties traded 266 contract(s) at a $240.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $279.3K, with a price of $1050.0 per contract. There were 1000 open contracts at this strike prior to today, and today 306 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be neutral, expiring in 43 day(s) on January 17, 2025. This event was a transfer of 99 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $89.1K, with a price of $900.0 per contract. There were 8479 open contracts at this strike prior to today, and today 289 contract(s) were bought and sold. 
• Regarding MEDP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), we observe a put option sweep with bullish sentiment. It expires in 15 day(s) on December 20, 2024. Parties traded 30 contract(s) at a $340.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $860.0 per contract. There were 224 open contracts at this strike prior to today, and today 178 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be neutral, expiring in 771 day(s) on January 15, 2027. This event was a transfer of 70 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $29.4K, with a price of $420.0 per contract. There were 4153 open contracts at this strike prior to today, and today 145 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 47 contract(s) at a $390.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $600.0 per contract. There were 348 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MEDP

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$86.00</td>
<td>$29.5K</td>
<td>72</td>
<td align="right">680</td>
</tr>
<tr>
<td>GEHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$84.00</td>
<td>$41.1K</td>
<td>24</td>
<td align="right">368</td>
</tr>
<tr>
<td>IBRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$4.50</td>
<td>$25.0K</td>
<td>635</td>
<td align="right">330</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$227.0K</td>
<td>99</td>
<td align="right">293</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$26.00</td>
<td>$94.8K</td>
<td>2.4K</td>
<td align="right">168</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$259.5K</td>
<td>533</td>
<td align="right">150</td>
</tr>
<tr>
<td>APLT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$33.0K</td>
<td>6.4K</td>
<td align="right">135</td>
</tr>
<tr>
<td>HROW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$31.9K</td>
<td>776</td>
<td align="right">118</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$240.00</td>
<td>$55.0K</td>
<td>491</td>
<td align="right">114</td>
</tr>
<tr>
<td>PSTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$44.2K</td>
<td>85</td>
<td align="right">110</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a put option sweep with bearish sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 674 contract(s) at a $86.00 strike. This particular put needed to be split into 44 different trades to become filled. The total cost received by the writing party (or parties) was $29.5K, with a price of $44.0 per contract. There were 72 open contracts at this strike prior to today, and today 680 contract(s) were bought and sold. 
• Regarding GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we observe a put option sweep with neutral sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 360 contract(s) at a $84.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.1K, with a price of $113.0 per contract. There were 24 open contracts at this strike prior to today, and today 368 contract(s) were bought and sold. 
• Regarding IBRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>), we observe a put option sweep with neutral sentiment. It expires in 168 day(s) on May 16, 2025. Parties traded 260 contract(s) at a $4.50 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $95.0 per contract. There were 635 open contracts at this strike prior to today, and today 330 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 112 day(s) on March 21, 2025. Parties traded 100 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $227.0K, with a price of $2270.0 per contract. There were 99 open contracts at this strike prior to today, and today 293 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, is expiring today. Parties traded 158 contract(s) at a $26.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $94.8K, with a price of $600.0 per contract. There were 2480 open contracts at this strike prior to today, and today 168 contract(s) were bought and sold. 
• Regarding BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we observe a call option sweep with bullish sentiment. It expires in 84 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $259.5K, with a price of $1730.0 per contract. There were 533 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• Regarding APLT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>), we observe a put option trade with bearish sentiment. It expires in 49 day(s) on January 17, 2025. Parties traded 110 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $300.0 per contract. There were 6422 open contracts at this strike prior to today, and today 135 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a put option sweep that happens to be bullish, expiring in 413 day(s) on January 16, 2026. This event was a transfer of 19 contract(s) at a $50.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $1680.0 per contract. There were 776 open contracts at this strike prior to today, and today 118 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a call option trade that happens to be bearish, expiring in 21 day(s) on December 20, 2024. This event was a transfer of 110 contract(s) at a $240.00 strike. The total cost received by the writing party (or parties) was $55.0K, with a price of $500.0 per contract. There were 491 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• For PSTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), we notice a call option trade that happens to be bullish, expiring in 49 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $44.2K, with a price of $442.0 per contract. There were 85 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLT

GEHC

HROW

IBRX

PSTX

10 Health Care Stocks With Whale Alerts In Today's Session

Investors with a lot of money to spend have taken a bullish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 37%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $747,642, and there was 1 call, for a total amount of $104,610.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $235.0 to $260.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Danaher's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Danaher's significant trades, within a strike price range of $235.0 to $260.0, over the past month.
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732129237_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$28.9</td>
<td>$28.4</td>
<td>$28.43</td>
<td>$260.00</td>
<td>$182.8K</td>
<td>1.6K</td>
<td align="right">136</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$29.7</td>
<td>$28.3</td>
<td>$28.41</td>
<td>$260.00</td>
<td>$154.1K</td>
<td>1.6K</td>
<td align="right">72</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$19.8</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$250.00</td>
<td>$152.8K</td>
<td>1.9K</td>
<td align="right">80</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$2.1</td>
<td>$1.9</td>
<td>$1.9</td>
<td>$235.00</td>
<td>$104.6K</td>
<td>557</td>
<td align="right">551</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$28.9</td>
<td>$28.5</td>
<td>$28.5</td>
<td>$260.00</td>
<td>$91.5K</td>
<td>1.6K</td>
<td align="right">212</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>With a volume of 1,313,444, the price of DHR is up 0.34% at $231.63. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>Expert Opinions on Danaher</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $305.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Danaher, maintaining a target price of $311. 
&#x2A; Reflecting concerns, an analyst from Stephens &amp; Co. lowers its rating to Overweight with a new price target of $315. 
&#x2A; An analyst from UBS persists with their Buy rating on Danaher, maintaining a target price of $305. 
&#x2A; An analyst from Wolfe Research upgraded its action to Outperform with a price target of $285. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Danaher with a target price of $310. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Markets

What the Options Market Tells Us About Danaher

Investors with a lot of money to spend have taken a bearish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 18% bullish and 81%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $574,327, and 2 are calls, for a total amount of $150,000.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $210.0 to $260.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Danaher stands at 431.56, with a total volume reaching 1,664.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Danaher, situated within the strike price corridor from $210.0 to $260.0, throughout the last 30 days.
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731701829_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.5</td>
<td>$11.0</td>
<td>$11.2</td>
<td>$230.00</td>
<td>$163.5K</td>
<td>1.3K</td>
<td align="right">139</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.9</td>
<td>$4.3</td>
<td>$4.9</td>
<td>$230.00</td>
<td>$147.0K</td>
<td>1.1K</td>
<td align="right">300</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$44.8</td>
<td>$42.7</td>
<td>$44.1</td>
<td>$230.00</td>
<td>$110.2K</td>
<td>0</td>
<td align="right">25</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$210.00</td>
<td>$62.8K</td>
<td>126</td>
<td align="right">699</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$31.6</td>
<td>$30.2</td>
<td>$30.7</td>
<td>$260.00</td>
<td>$61.4K</td>
<td>205</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Danaher</h3>
<ul>
<li>With a trading volume of 3,258,575, the price of DHR is down by -1.73%, reaching $235.23.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>Expert Opinions on Danaher</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $288.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Danaher, which currently sits at a price target of $315. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Danaher, maintaining a target price of $275. 
&#x2A; An analyst from Baird persists with their Outperform rating on Danaher, maintaining a target price of $277. 
&#x2A; An analyst from Stifel persists with their Hold rating on Danaher, maintaining a target price of $265. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Danaher, targeting a price of $310. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

WIIM

Danaher shares are trading lower after Third Point in a 13F disclosed that it decreased its stake in the company by 5%

AAPL

MSFT

Third Point 13F Shows Decreased Stake In PG&E Corp By 7% From 53,750,000 To 49,750,000 Shares; Amazon By 27% From 5,100,000 To 3,700,000 Shares; Danaher Corp By 5% From 2,050,000 To 1,950,000 Shares; Vistra Corp By 29% From 4,470,000 To 3,175,000 Shares; Microsoft By 45% From 1,580,000 To 870,000 Shares; Meta Platforms By 50% From 1,100,000  To 545,000 Shares; TSM By 12% From 2,025,000 To 1,780,000 Shares; Apple By 52% From 1,950,000 To 930,000 Shares; Amphenol Corp By 43% From 2,800,000 To 1,600,000 Shares

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has fallen 5.68% since its last report. The company recently reported that it has 5.32 million shares sold short, which is 0.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730733432_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 5.39%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Danaher's Recent Short Interest

In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) in relation to its major competitors in the Life Sciences Tools &amp; Services industry. Through a detailed examination of key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and illuminate company's performance in the industry.
<h3>Danaher Background</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danaher Corp</td>
<td>46.75</td>
<td>3.49</td>
<td>7.74</td>
<td>1.62%</td>
<td>$1.66</td>
<td>$3.4</td>
<td>3.09%</td>
</tr>
<tr>
<td>Thermo Fisher Scientific Inc</td>
<td>34.98</td>
<td>4.36</td>
<td>5.06</td>
<td>3.38%</td>
<td>$2.91</td>
<td>$4.35</td>
<td>0.54%</td>
</tr>
<tr>
<td>Agilent Technologies Inc</td>
<td>28.46</td>
<td>6.66</td>
<td>6.19</td>
<td>4.65%</td>
<td>$0.43</td>
<td>$0.85</td>
<td>-5.62%</td>
</tr>
<tr>
<td>IQVIA Holdings Inc</td>
<td>27.48</td>
<td>5.45</td>
<td>2.52</td>
<td>4.17%</td>
<td>$0.8</td>
<td>$1.38</td>
<td>4.28%</td>
</tr>
<tr>
<td>Waters Corp</td>
<td>36.95</td>
<td>14.34</td>
<td>7.92</td>
<td>10.71%</td>
<td>$0.24</td>
<td>$0.42</td>
<td>4.02%</td>
</tr>
<tr>
<td>West Pharmaceutical Services Inc</td>
<td>46.96</td>
<td>8.33</td>
<td>8.15</td>
<td>5.1%</td>
<td>$0.21</td>
<td>$0.26</td>
<td>-0.07%</td>
</tr>
<tr>
<td>Avantor Inc</td>
<td>49.58</td>
<td>2.73</td>
<td>2.23</td>
<td>1.05%</td>
<td>$0.23</td>
<td>$0.56</td>
<td>-0.34%</td>
</tr>
<tr>
<td>Revvity Inc</td>
<td>75.65</td>
<td>1.90</td>
<td>5.52</td>
<td>0.7%</td>
<td>$0.22</td>
<td>$0.39</td>
<td>-2.45%</td>
</tr>
<tr>
<td>Bio-Techne Corp</td>
<td>79.27</td>
<td>5.59</td>
<td>10.32</td>
<td>1.6%</td>
<td>$0.07</td>
<td>$0.2</td>
<td>-5.44%</td>
</tr>
<tr>
<td>Medpace Holdings Inc</td>
<td>27.98</td>
<td>11.27</td>
<td>4.94</td>
<td>11.72%</td>
<td>$0.12</td>
<td>$0.17</td>
<td>8.29%</td>
</tr>
<tr>
<td>Charles River Laboratories International Inc</td>
<td>21.65</td>
<td>2.51</td>
<td>2.29</td>
<td>2.44%</td>
<td>$0.24</td>
<td>$0.35</td>
<td>-3.19%</td>
</tr>
<tr>
<td>Bruker Corp</td>
<td>24.81</td>
<td>5.02</td>
<td>2.79</td>
<td>0.47%</td>
<td>$0.08</td>
<td>$0.38</td>
<td>17.42%</td>
</tr>
<tr>
<td>Stevanato Group SpA</td>
<td>39.22</td>
<td>4.39</td>
<td>4.43</td>
<td>1.55%</td>
<td>$0.05</td>
<td>$0.07</td>
<td>1.67%</td>
</tr>
<tr>
<td>Sotera Health Co</td>
<td>113.29</td>
<td>10.62</td>
<td>4.10</td>
<td>2.05%</td>
<td>$0.1</td>
<td>$0.15</td>
<td>8.35%</td>
</tr>
<tr>
<td>Average</td>
<td>46.64</td>
<td>6.4</td>
<td>5.11</td>
<td>3.81%</td>
<td>$0.44</td>
<td>$0.73</td>
<td>2.11%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Upon a comprehensive analysis of Danaher, the following trends can be discerned: 
<ul>
<li>
The Price to Earnings ratio of 46.75 for this company is 1.0x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
With a Price to Book ratio of 3.49, significantly falling below the industry average by 0.55x, it suggests undervaluation and the possibility of untapped growth prospects.
</li>
<li>
The stock's relatively high Price to Sales ratio of 7.74, surpassing the industry average by 1.51x, may indicate an aspect of overvaluation in terms of sales performance.
</li>
<li>
The company has a lower Return on Equity (ROE) of 1.62%, which is 2.19% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
With higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.66 Billion, which is 3.77x above the industry average, the company demonstrates stronger profitability and robust cash flow generation.
</li>
<li>
Compared to its industry, the company has higher gross profit of $3.4 Billion, which indicates 4.66x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company is experiencing remarkable revenue growth, with a rate of 3.09%, outperforming the industry average of 2.11%.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730732622_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing Danaher against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
Danaher exhibits a stronger financial position compared to its top 4 peers in the sector, as indicated by its lower debt-to-equity ratio of 0.34.
</li>
<li>
This suggests that the company has a more favorable balance between debt and equity, which can be seen as a positive aspect for investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Danaher in the Life Sciences Tools &amp; Services industry, the PE ratio is high compared to peers, indicating potential overvaluation. The PB ratio is low, suggesting a possible undervaluation relative to industry standards. The PS ratio is high, signaling a premium valuation based on sales. In terms of ROE, Danaher shows lower profitability compared to peers. However, its high EBITDA, gross profit, and revenue growth reflect strong operational performance within the industry sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Inquiry Into Danaher's Competitor Dynamics In Life Sciences Tools &amp; Services Industry

RBC Capital analyst Conor McNamara maintained a Buy rating on Danaher (DHR – Research Report) on January 10 and set a price target of $308.00. The ...

RBC Capital Sticks to Its Buy Rating for Danaher (DHR)

Mawer Investment Management Q4 2024 Quarterly Update

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nuvalent (NUVL – Research Report) and Danaher (DHR...

Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Danaher (DHR)

In a report released today, Luke Sergott from Barclays maintained a Hold rating on Danaher (DHR – Research Report), with a price target of $275.00....

Danaher (DHR) Gets a Hold from Barclays

Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Danaher (DHR – Research Report) yesterday and set a price target of $2...

Danaher Secures Buy Rating Amid Strong Q4 Performance and Promising Growth Prospects

Franklin DynaTech Fund Q4 2024 Commentary

Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued

U.S. commerce dept. sets export controls on certain lab instruments

Goldman Sachs analyst Matthew Sykes lowered the firm's price target on Danaher (DHR) to $250 from $255 and keeps a Neutral rating on the shares aft...

Danaher price target lowered to $250 from $255 at Goldman Sachs

ASHTF

ASHTY

ASMIY

ASML

ASMLF

ASMXF

AVGO

AXON

AZNCF

BRKR

BZLFF

BZLFY

CCDBF

CCLLF

CMPGF

CMPGY

CTSDF

FINGF

GOOG

GOOGL

HUBS

IAFNF

ICLR

KLAC

LRCX

MPWR

NONOF

NUVL

NVDA

STLJF

TMTNF

TROLB

TRRVF

TSLA

TSMWF

WOLTF

WTKWY

Press Releases

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

Danaher Schedules Third Quarter 2024 Earnings Conference Call

Danaher Reports Third Quarter 2024 Results

Danaher to Present at Evercore ISI HealthCONx Conference

Dividends

Danaher Announces Quarterly Dividend

Danaher Schedules Fourth Quarter 2024 Earnings Conference Call

Danaher to Present at J.P. Morgan Healthcare Conference

Danaher Announces Investment Partnership in Innovaccer Inc.

Danaher CEO to Comment on Financial Performance

Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Danaher

뉴스

에 대한 최신 뉴스 Danaher (NYSE:DHR) 주식

토요일, 12월 14, 2024

화요일, 10월 22, 2024

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌